8/9/2019 Ophthalmic Products Presentation
1/19
Ophthalmics
Antiglaucomatic agents
Products presentation
NSAID
8/9/2019 Ophthalmic Products Presentation
2/19
Antiglaucomatic agents
Corneax
(brimonidine)
Ophthalmics
Dorolad (dorzolamide)
Dotiz
(dorzolamide + timolol)
X-iop
(latanoprost)
Tinoprost (latanoprost + timolol)
8/9/2019 Ophthalmic Products Presentation
3/19
Product characteristics
Active in redient:Brimonidine tartrate
Corneax
Pharmaceutical form:Eye drops, solution
Route of administration:Ophthalmic use
Strength:0,2% w/w
Packaging:1 vial x 5 ml
8/9/2019 Ophthalmic Products Presentation
4/19
Therapeutic indications - dosage
Corneax
is indicated for the reduction of elevated intraocular ressure
Corneax
(IOP) in patients with open angle glaucoma or ocular hypertension:
as monotherapy, in patients in whom topical beta-blocker therapy is
contraindicated
as adjunctive therapy to other intraocular pressure lowering
medications, when the target IOP is not achieved with a single agent
Dosage: one drop to each eye(s) twice daily, ~12 hours apart
8/9/2019 Ophthalmic Products Presentation
5/19
Product characteristics
Active in redient:Dorzolamide as h drochloride
Dorolad
Pharmaceutical form:Eye drops, solution
Route of administration:Ophthalmic use
Strength:2% w/w
Packaging:1 vial x 5 ml
8/9/2019 Ophthalmic Products Presentation
6/19
8/9/2019 Ophthalmic Products Presentation
7/19
Product characteristics
Active in redients: Dorzolamide as h drochloride + Timolol as
Dotiz
maleate)
Pharmaceutical form:Eye drops, solution
Route of administration:Ophthalmic use Strength:2,0%+0,5% w/v
Packaging:1 vial x 5 ml
8/9/2019 Ophthalmic Products Presentation
8/19
Therapeutic indications - dosage
Dotiz
is indicated for the treatment of elevated intraocular ressure
Dotiz
(IOP) in patients with open-angle glaucoma or pseudoexfoliative
glaucoma when topical beta-blocker monotherapy is not sufficient
Dosage: one drop, twice daily
8/9/2019 Ophthalmic Products Presentation
9/19
Product characteristics
Active in redient:Latano rost
X-iop
Pharmaceutical form:Eye drops, solution
Route of administration:Ophthalmic use
Strength:0,005% w/v
Packaging:1 vial x 2,5 ml
8/9/2019 Ophthalmic Products Presentation
10/19
Therapeutic indications - dosage
X-io
is indicated for the treatment of elevated intraocular ressure
X-iop
(IOP) in patients with open-angle glaucoma or ocular hypertension
Dosage: one drop, once daily. It is recommended to use the product at
night before bedtime
8/9/2019 Ophthalmic Products Presentation
11/19
Product characteristics
Active in redient:Latano rost + Timolol as maleate
Tinoprost
Pharmaceutical form:Eye drops, solution
Route of administration:Ophthalmic use
Strength:(50 mcg + 5 mg)/ml
Packaging:1 vial x 2,5 ml
8/9/2019 Ophthalmic Products Presentation
12/19
Therapeutic indications - dosage
Tino rost
is indicated for the treatment of elevated intraocular
Tinoprost
pressure (IOP) in patients with open-angle glaucoma or ocular
hypertension, where treatment with -blockers or prostaglandin
analogues
Dosage: one drop, once daily
8/9/2019 Ophthalmic Products Presentation
13/19
Ophthalmics
Antimicrobial agent
8/9/2019 Ophthalmic Products Presentation
14/19
Product characteristics
Lexacin
Pharmaceutical form:Eye drops, solution
Route of administration:Ophthalmic use
Strength:0,5% w/v
Packaging:1 vial x 10 ml
8/9/2019 Ophthalmic Products Presentation
15/19
Therapeutic indications - dosage
Lexacin
from bacteria (including bacteria conjunctivitis) and microorganisms
susceptible to levofloxacin, in adults and children over 1 year old
Dosage:
1st-2nd day: 1-2 drops in the affected eye(s) every 2 hours, up to 8
times daily
3rd-5th day: 1-2 drops in the affected eye(s), 4 times daily
8/9/2019 Ophthalmic Products Presentation
16/19
Therapeutic indications - dosage
Lexacin
prophylaxis and post operative therapy of patients that have undergone
cataract surgery
Dosage:
1 drop, 1 hour before surgery; 1 drop, 30 minutes before surgery
followed by 3 drops at 5-minute intervals just after surgery and
4 drops daily for 6 days staring the day after surgery
Ref: ESCRS Endophthalmitis Study Group, J Cataract Refract Surg 2007
8/9/2019 Ophthalmic Products Presentation
17/19
Ophthalmics
NSAID
Errkes
8/9/2019 Ophthalmic Products Presentation
18/19
Product characteristics
Active ingredient:Ketorolac trometamol
Errkes
Pharmaceutical form:Eye drops, solution
Route of administration:Ophthalmic use
Strength:0,5% w/v
Packaging:1 vial x 10 ml
8/9/2019 Ophthalmic Products Presentation
19/19
Therapeutic indications - dosage
Errkes
is indicated for the prevention and treatment of ocular
Errkes
inflammation after cataract surgery
Dosage: one drop, three times daily, starting 24 hours before
surgery and after surgery for 3-4 weeks
Errkes
is also indicated for the temporary relief of ocular itching due to
seasonal allergic conjunctivitis
Dosage: one drop, four times daily to the affected eye(s)
Top Related